Ryan Caputo highlights the DanGer Shock and REDUCE-AMI trials, both released at ACC 2024. This is Part I in a 2-part rapid reaction series from ACC 2024.

Ryan Caputo joins me to highlight 2 of the most practice-changing research studies, DanGer Shock and REDUCE-AMI, published during ACC 2024 in Part 1 of the 2-part rapid reaction episode series.

We start by discussing DanGer Shock, published in NEJM. How is an impella pump different from other forms of mechanical circulatory support (MCS)? What are research challenges with cardiogenic shock patients? Was this routine use? What questions still remain? Safety v. efficacy findings, DanGer Shock v. IABP-SHOCK II & ECLS-SHOCK, pharmacotherapy fun facts, and much more.

Then we highlight the REDUCE-AMI trial, also published in NEJM. What’s the historical evidence for beta blocker use post-MI? What do the guidelines recommend? Should every trial have an expiration date? How do quality metrics affect ability to deprescribe? Comparing patient populations in this study v. older studies, and much more.